CDA: Cytidine deaminase
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis. {ECO:0000269|PubMed:7923172, ECO:0000269|PubMed:9596658}.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on CDA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Cedazuridine | Approved | Otsuka Beijing Research Institute | Small molecule | InhibitorCytidine deaminase inhibitor | 54 |
- Myelodysplastic syndrome0.51
- Myeloid leukemia0.39
- Acute myeloid leukemia0.38
- Chronic myelomonocytic leukemia0.34
- Neurodegenerative disease0.32
- Atrioventricular block0.19
- Myeloid neoplasm0.18
- Neoplasm0.11
- Pancreatic ductal adenocarcinoma0.10
- Cancer0.10
- Breast cancer0.10
- Chronic myeloid leukemia0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4502, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P32320, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets